Accessibility StatementSkip Navigation New 82,514 square foot facility will accommodate up to 15 biotech companies to fuel next-generation medicines Gateway Labs model provides flexible lab space and tailored scientific engagement to support early-stage biotechs INDIANAPOLIS, Sept. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the official opening of its newest Lilly Gateway Labs (LGL) site in San Diego, California, expanding its network of shared innovation hubs designed to s ...

THOUSAND OAKS, Calif., Sept. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 9:15 a.m. ET on September 9, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the ...

Core Viewpoint - Amgen will present at the 2025 Wells Fargo Healthcare Conference, highlighting its ongoing commitment to innovation in the biotechnology sector [1][2]. Company Overview - Amgen is a leader in discovering, developing, manufacturing, and delivering innovative medicines aimed at treating serious diseases [3]. - The company has a robust pipeline that focuses on various therapeutic areas, including cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases [3]. Recognition and Market Position - In 2024, Amgen received accolades such as being named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes [4]. - Amgen is included in the Dow Jones Industrial Average® and the Nasdaq-100 Index®, reflecting its status as one of the largest and most innovative non-financial companies based on market capitalization [4].

In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X, LinkedIn ...

Group 1 - Amgen will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, at 9:20 a.m. PT, featuring executives Peter Griffith and Jay Bradner [1] - The webcast of the presentation will be available on Amgen's website and archived for at least 90 days [2] - Amgen is recognized for its innovative medicines and has a strong pipeline targeting various diseases, including cancer and heart disease [3] Group 2 - In 2024, Amgen received accolades such as being named one of the "World's Most Innovative Companies" and "America's Best Large Employers" [4] - Amgen is part of the Dow Jones Industrial Average and the Nasdaq-100 Index, highlighting its market significance [4]

Company Overview - Amgen is a biotechnology company that discovers, develops, manufactures, and delivers innovative medicines to combat serious diseases [3] - The company has a broad and deep pipeline aimed at treating cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases [3] - Amgen has been recognized as one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes in 2024 [4] Upcoming Events - Amgen will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 9:20 a.m. ET [1] - The presentation will be made by Peter Griffith, CFO, and Murdo Gordon, EVP of Global Commercial Operations [1] - The webcast of the presentation will be available for replay for at least 90 days after the event [2]

Core Viewpoint - Amgen is set to report its first quarter 2025 financial results on May 1, 2025, followed by a conference call with senior management [1] Group 1: Financial Reporting - Amgen will announce its Q1 2025 financial results after the close of U.S. financial markets on May 1, 2025 [1] - A conference call will take place at 4:30 p.m. ET, featuring CEO Robert A. Bradway and other senior management members [1] Group 2: Conference Call Details - The conference call will be broadcast live over the internet, accessible to media, investors, and the general public [2] - The webcast will be archived for at least 90 days for replay [3] Group 3: Company Overview - Amgen is a leader in biotechnology, focusing on innovative medicines for serious diseases, with over 40 years of industry experience [4] - The company has a diverse pipeline targeting cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases [4] Group 4: Recognition and Index Inclusion - In 2024, Amgen was recognized as one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes [5] - Amgen is part of the Dow Jones Industrial Average and the Nasdaq-100 Index, highlighting its market capitalization and innovation [5]